Transarterial Radioembolization Agents: a Review of the Radionuclide Agents and the Carriers
10.1007/s13139-021-00709-3
- Author:
Aysheh ALRFOOH
1
;
Aditi PATEL
;
Sandeep LAROIA
Author Information
1. University of Iowa, 200 Hawkins Drive, Iowa City, IA 52242, USA
- Publication Type:REVIEW
- From:Korean Journal of Nuclear Medicine
2021;55(4):162-172
- CountryRepublic of Korea
- Language:English
-
Abstract:
Liver tumors, both primary and secondary to metastatic disease, remain a major challenge, with an increasing incidence. In this context, taking advantage of the dual blood supply of the liver, and the fact that liver tumors derive majority of their blood supply from the hepatic artery, intraarterial therapies are gaining popularity. Intraarterial liver-directed therapy (IALDT) is the option when the surgery is not feasible due to the number of metastases or for other reasons. Transarterial radioembolization (TARE) is a specific type of IALDT, where a carrier particle/microsphere is labeled with a radioactive substance and then is injected into hepatic artery for therapeutic purposes. As this field is rapidly evolving, with multiple agents being investigated and being introduced into clinical practice, it is hard for the practitioners and researchers to encompass all the available information concisely. This article aims to present a comprehensive review of the prominent TARE technologies.
